Official Title
Real-world Effectiveness of Oral Antivirals for Treatment of COVID-19 in Ministry of Health Malaysia Institutions
Brief Summary

This study is a prospective observational cohort study to evaluate the benefit of oralantivirals (nirmatrelvir plus ritonavir or molnupiravir) in Ministry of Healthinstitutions. In this study, we will observe the progress of COVID-19 study participantsseen in the health clinic up to 90 days from their initial visit to the health clinic.

Detailed Description

This protocol is a prospective, multi-center, observational cohort study to evaluate the
benefit of oral antivirals (nirmatrelvir plus ritonavir or molnupiravir) in Ministry of
Health institutions in preventing progression of COVID-19 to severe COVID-19.

In this study, we will observe the clinical outcomes (COVID-19 symptoms, hospitalization
admission, mortality, long term COVID-19 symptoms) of COVID-19 study participants seen in
the health clinic up to 90 days from their initial visit to the health clinic . The
hypothesis is that oral antiviral is beneficial in preventing disease progression and
reducing long term COVID-19 symptoms.

Recruiting
COVID-19

Drug: Oral Antiviral

Nirmatrelvir plus ritonavir or molnupiravir
Other Name: Paxlovid,Lagevrio

Eligibility Criteria

Inclusion Criteria:

- All SARS-CoV-2 positive individuals who are eligible for oral antiviral treatment
based on current Ministry of Health Malaysia guidelines.

Exclusion Criteria:

- Individual who received oral antiviral (either nirmatrelvir plus ritonavir or
monupiravir) more than 5 days following their positive SARS-CoV-2 test date

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Malaysia
Locations

Klinik Kesihatan Kajang
Kajang, Selangor, Malaysia

Klinik Kesihatan Banadar Botanik
Klang, Selangor, Malaysia

Klinik Kesihatan Bukit Kuda
Klang, Selangor, Malaysia

Klinik Kesihatan Pandamaran
Klang, Selangor, Malaysia

Klinik Kesihatan Seksyen 19
Petaling Jaya, Selangor, Malaysia

Klinik Kesihatan Seksyen 7
Petaling Jaya, Selangor, Malaysia

Klinik Kesihatan Puchong Batu 14
Subang Jaya, Selangor, Malaysia

Klinik Kesihatan Taman Medan
Petaling Jaya, Malaysia

Contacts

Ee Vien Low, Ph.D.
+60333628829
evlow@moh.gov.my

Mohan Dass Pathamanathan, MD
+60333628628
drmohandass@moh.gov.my

Ee Vien Low, Ph.D., Principal Investigator
Clinical Research Center, Malaysia

Clinical Research Centre, Malaysia
NCT Number
Keywords
oral antivirals
High risk patients
MeSH Terms
COVID-19
Antiviral Agents